Related Research Articles
Safe sex is sexual activity using methods or contraceptive devices to reduce the risk of transmitting or acquiring sexually transmitted infections (STIs), especially HIV. "Safe sex" is also sometimes referred to as safer sex or protected sex to indicate that some safe sex practices do not eliminate STI risks. It is also sometimes used colloquially to describe methods aimed at preventing pregnancy that may or may not also lower STI risks.
Men who have sex with men (MSM) refers to all men who engage in sexual activity with other men, regardless of sexual identity. The term was created by epidemiologists in the 1990s, to better study and communicate the spread of sexually transmitted infections such as HIV/AIDS between all sexually active males, not strictly those identifying as gay or bisexual, but also for example male prostitutes. The term is often used in medical literature and social research to describe such men as a group. It does not describe any specific kind of sexual activity, and which activities are covered by the term depends on context. An alternative term, males who have sex with males is sometimes considered more accurate in cases where those described may not be legal adults.
Post-exposure prophylaxis, also known as post-exposure prevention (PEP), is any preventive medical treatment started after exposure to a pathogen in order to prevent the infection from occurring.
Emtricitabine/tenofovir, sold under the brand name Truvada among others, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains the antiretroviral medications emtricitabine and tenofovir disoproxil. For treatment, it must be used in combination with other antiretroviral medications. For prevention before exposure, in those who are at high risk, it is recommended along with safer sex practices. It does not cure HIV/AIDS. Emtricitabine/tenofovir is taken by mouth.
Pre-exposure prophylaxis for HIV prevention, commonly known as PrEP, is a form of pre-exposure prophylaxis to prevent HIV infection, the cause of HIV/AIDS.
The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. HPTN studies evaluate new HIV prevention interventions and strategies in populations and geographical regions that bear a disproportionate burden of infection. The HPTN is committed to the highest ethical standards for its clinical trials and recognizes the importance of community engagement in all phases of the research process.
HIV/AIDS was first diagnosed in 1981. As of year-end 2018, 160,493 people have been diagnosed with HIV in the United Kingdom and an estimated 7,500 people are living undiagnosed with HIV. New diagnoses are highest in gay/bisexual men, with an estimated 51% of new diagnosis reporting male same-sex sexual activity as the probable route of infection. Between 2009 and 2018 there was a 32% reduction in new HIV diagnosis, attributed by Public Health England (PHE) to better surveillance and education. PHE has described an "outbreak" in Glasgow amongst people who inject drugs, and has campaigns targeting men who have sex with men in London and other major cities. London was the first city in the world to reach the World Health Organization target for HIV, set at 90% of those with HIV diagnosed, 90% of those diagnosed on HAART and 90% of those on HAART undetectable. The UK as a whole later achieved the same target. Under the Equality Act 2010, it is illegal to discriminate against someone based on their HIV status in the UK.
The history of HIV/AIDS in Australia is distinctive, as Australian government bodies recognised and responded to the AIDS pandemic relatively swiftly, with the implementation of effective disease prevention and public health programs, such as needle and syringe programs (NSPs). As a result, despite significant numbers of at-risk group members contracting the virus in the early period following its discovery, Australia achieved and has maintained a low rate of HIV infection in comparison to the rest of the world.
There is a relatively low prevalence of HIV/AIDS in New Zealand, with an estimated 2,900 people out a population of 4.51 million living with HIV/AIDS as of 2014. The rate of newly diagnosed HIV infections was stable at around 100 annually through the late 1980s and the 1990s but rose sharply from 2000 to 2005. It has since stabilised at roughly 200 new cases annually. Male-to-male sexual contact has been the largest contributor to new HIV cases in New Zealand since record began in 1985. Heterosexual contact is the second largest contributor to new cases, but unlike male-to-male contact, they are mostly acquired outside New Zealand. In 2018 the New Zealand Government reported a “major reduction” in the number of people diagnosed with HIV.
HIV/AIDS was first detected in Canada in 1982. In 2018, there were approximately 62,050 people living with HIV/AIDS in Canada. It was estimated that 8,300 people were living with undiagnosed HIV in 2018. Mortality has decreased due to medical advances against HIV/AIDS, especially highly active antiretroviral therapy (HAART).
The National AIDS Trust is a United Kingdom charity with the purpose to stand alongside and defend the rights of everyone living with, affected by or at risk of HIV. Its expertise, research and advocacy secure lasting change to the lives of people living with and at risk of HIV. The charity's key strategic goals are:
iPrEx was a phase III clinical trial to determine whether the antiretroviral medication emtricitabine/tenofovir could safely and effectively prevent HIV acquisition through sex in men who have sex with men and transgender women. iPrEx was the first human study of an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP.
HIV prevention refers to practices that aim to prevent the spread of the human immunodeficiency virus (HIV). HIV prevention practices may be undertaken by individuals to protect their own health and the health of those in their community, or may be instituted by governments and community-based organizations as public health policies.
Elioda Tumwesigye is a Ugandan politician, physician, and epidemiologist who has served as minister of science, technology and innovation in the cabinet of Uganda since June 2016. From March 2015 until June 2016, he served as the minister of health.
HPTN 083 is a 2016 clinical trial which compares cabotegravir injections with oral use of Emtricitabine/tenofovir as pre-exposure prophylaxis ("PrEP") for prevention of HIV/AIDS.
56 Dean Street, based in Dean Street in London's Soho district, is a sexual health clinic. Part of the Chelsea and Westminster Hospital NHS Foundation Trust, it also has a second branch, Dean Street Express, at 34 Dean Street, which offers a fast-turnaround testing service. As of 2017, the clinic was the largest HIV clinic in Europe. In addition to its specialism in HIV infection and other sexually transmitted diseases, it also offers general sexual health care services, including contraception. The clinic also runs TransPlus - the UK’s first integrated NHS gender dysphoria, sexual health and HIV service.
Margaret Denise Portman was a British medical doctor who specialised in sexual health. She was an advocate for pre-exposure prophylaxis medication (PrEP) to prevent new HIV cases.
Greg Owen is a UK-born activist who started a website to make generic pre-exposure prophylaxis medication (PrEP) accessible to prevent HIV infection.
In January 2018, the provincial government of British Columbia (BC) began providing individuals at high risk of HIV infection with pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) at no cost. High risk individuals include men and trans women who have sex with men, people who inject drugs, and people who have sex with people living with HIV. One year following this policy change, which is delivered as part of the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE)'s Drug Treatment Program, almost 3,300 people have been prescribed with PrEP or PEP.
Pre-exposure prophylaxis (PrEP), is the use of medications to prevent the spread of disease in people who have not yet been exposed to a disease-causing agent. Vaccination is the most commonly used form of pre-exposure prophylaxis; other forms of pre-exposure prophylaxis generally involve drug treatment, known as chemoprophylaxis. Examples include taking medication to prevent infection by malaria or HIV. In particular, the term PrEP is now synonymous in popular usage with the use of pre-exposure prophylaxis for HIV prevention.
References
- ↑ "HIV campaigners win NHS drug battle". BBC News Online . 2 August 2016. Retrieved 2 August 2016.
- ↑ "Councils and charity win High Court battle over HIV treatment decision". Local Government Lawyer. 2 August 2016. Retrieved 2 August 2016.
- ↑ "Judge urged to overturn NHS decision not to fund HIV prevention treatment". The Guardian . Press Association. 13 July 2016. ISSN 0261-3077 . Retrieved 2 August 2016.
- ↑ Boseley, Sarah (2 August 2016). "NHS can fund 'game-changing' PrEP HIV drug, court says". The Guardian . ISSN 0261-3077 . Retrieved 2 August 2016.
- ↑ "NHS England loses HIV drug judicial review". Health Service Journal. 2 August 2016. Retrieved 27 October 2016.
- ↑ [2016] EWCA (Civ) 1100
- ↑ Strudwick, Patrick (10 November 2016). "NHS England loses its appeal and could now provide the HIV prevention drug". BuzzFeed . Retrieved 11 March 2017.
- ↑ Strudwick, Patrick (4 December 2016). "The HIV prevention drug will now be made available to thousands of people". BuzzFeed . Retrieved 11 March 2017.
- 1 2 Strudwick, Patrick (5 January 2017). "This is how much the NHS spent trying to avoid paying for the HIV prevention drug". BuzzFeed . Retrieved 11 March 2017.